IMforte: NCT05091567: Phase 3: Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
(A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte))
ClinicalTrials.gov ID: NCT05091567 — IMforte
Official Title: A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab
Primary Publication: Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Authors: Luis Paz-Ares, Hossein Borghaei, Stephen V. Liu, Solange Peters, Roy S. Herbst, et al.; IMforte investigators
Journal: The Lancet - Year: 2025
FDA Approval — YES; Approval Date: October 2, 2025
FDA Announcement: FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer.
NCCN Supported — YES
Zepzelca (lurbinectedin) — Jazz Pharmaceuticals
Tecentriq (atezolizumab) — Genentech